Published in Women's Health Weekly, December 25th, 2003
Phenoxodiol is currently in phase II human clinical trials in the U.S. and Australia, and the rights to commercialize phenoxodiol have been licensed to the Novogen majority-owned U.S. company Marshall Edwards, Inc.
Novogen Managing Director Christopher Naughton said the latest patent joined a suite of existing protection that consolidated and further secured Novogen's intellectual property...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly